Core Viewpoint - The company, Boladeli, emphasizes the importance of original research in the pet pharmaceutical industry to enhance the reputation of domestic products in China [2]. Group 1: Company Achievements - Boladeli has been operating in the Taizhou Medical High-tech Industrial Development Zone since 2018, focusing on the research and production of innovative pet pharmaceuticals and functional health products [2]. - The company has received a total of 9 national new veterinary drug registration certificates, including 1 globally innovative Class I new veterinary drug and 4 nationally innovative Class II new veterinary drugs [2]. - In 2025 alone, Boladeli achieved a record of obtaining 5 new veterinary drug registration certificates [2]. - Over 17 additional products are currently in the new veterinary drug registration process, with more than half being globally and domestically original innovations [2]. Group 2: Product Innovations - The "Miao Bei Hu" cat trivalent vaccine, China's first approved Class II new veterinary drug, utilizes local prevalent strains and advanced production techniques to enhance safety [3]. - The "Miao Bei Jian" recombinant cat interferon is the first approved in China and the second globally, designed for both injection and eye drop use, marking significant progress in pet gene engineering drug development in China [3]. Group 3: Industry Context - The pet medical market in China is rapidly expanding due to the increasing role of pets in families, leading to a growing demand for safe, reliable, and sustainably supplied domestic drugs and vaccines [2]. - Boladeli's investment of over 200 million yuan in building a comprehensive R&D and production base in accordance with EU standards reflects its commitment to accelerating the industrialization of new products [3][4]. - The ongoing growth of the pet economy is attributed to the deepening emotional connection between humans and pets, with Boladeli aiming to provide high-quality domestic pet pharmaceuticals [4].